drugset / Trial / NCT04518475
Eltrombopag Combining Rituximab Versus Eltrombopag in the Management of Primary Immune Thrombocytopenia (ITP) in Adults
Phase 4
Recruiting
224 enrolled
Institute of Hematology & Blood Diseases Hospital, China
Affiliated Hospital of Nantong University · collabHenan Cancer Hospital · collabThe First Affiliated Hospital of Xiamen University · collabThe Second Affiliated Hospital of Kunming Medical University · collabTianjin Medical University Second Hospital · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This multicenter randomized, open-label study aimed to compare the efficacy and safety of eltrombopag combining rituximab with eltrombopag in China adult ITP patients .This study was be conducted in adult ITP patients who had not responded to or had relapsed after previous treatment of ITP, including first line therapy and /or splenectomy.
Timeline
- Start
- 2020-08-10
- Primary completion
- 2029-02-10
- Completion
- 2030-08-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Eltrombopag | Small molecule | 75 mg | Oral |
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | Other |